Latest news with #ClickTherapeutics
Yahoo
26-05-2025
- Business
- Yahoo
Digital Therapeutics Market Analysis and Forecasts, 2025-2035: Rising Fundings and Investment in Digital Therapeutics and Expanding Applications Driving Opportunities
The global digital therapeutics market is rapidly transforming healthcare with evidence-based software and devices that enhance both physical and behavioral health management. Key drivers include increased accessibility, patient engagement, data insights, and reduced healthcare costs. Notable developments in the market feature major collaborations between prominent firms like Vida Health and Click Therapeutics. With challenges like data privacy and reimbursement hindrances, expanding applications and rising investment present vast opportunities for growth. This dynamic market is fueled by technological advances, cost-effectiveness, and expanding global reach, signifying a new era in personalized, patient-centered care. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Digital Therapeutics Market - A Global and Regional Analysis: Focus on Product Type, Application, Sales Channel, and Country - Analysis and Forecast, 2025-2035" report has been added to global digital therapeutics market includes clinically validated software and devices that are evidence-based. These tools are intended for the treatment of a wide range of diseases and conditions. Furthermore, digital therapeutics can be used either on their own or in combination with other devices to manage both physical and behavioural health issues. China led the Asia-Pacific digital therapeutics market in 2024, driven by its large population facing chronic conditions like diabetes, hypertension, and cardiovascular diseases. Digital therapeutics provides effective and accessible solutions for managing these health issues. The Chinese government acknowledges the potential of digital therapeutics and is actively supporting its development and adoption to improve healthcare delivery and outcomes. How can this report add value to an organization?Product/Innovation Strategy: The global digital therapeutics market is extensively segmented across various categories, such as product type, application, sales channel, and region. Each region undergoes a detailed analysis based on digital therapeutics product type, application, and sales channel. This segmentation offers readers a clear overview of which digital therapeutics segments currently dominate the market, and which ones are well-positioned for growth in the Strategy: Synergistic activities represented the largest share of key developments, with approximately 64.44% of all developments in the global digital therapeutics market occurring between January 2020 and November Strategy: The global digital therapeutics market is home to numerous established players, each offering product portfolios that address a wide array of conditions. Key players analysed and profiled in the study include prominent companies providing diverse digital therapeutics solutions for treatment, patient care, and preventive Dynamics Impact Analysis: Increased Accessibility of Care Improved Patient Engagement and Adherence Enhanced Data Collection and Analysis Reduced Costs of Healthcare Delivery Market Demand Drivers Multiple Benefits Provided by Digital Therapeutics over Traditional Treatment Continuous Technological Advancements Driving the Adoption of Digital Therapeutics Increasing Demand for Cost-Effective Solutions Creating a Demand for Digital Therapeutics Market Restraints: Data Privacy and Security Concerns Lack of Standardized Reimbursement Models Market Opportunities: Expanding Applications of Digital Therapeutics Rising Fundings and Investment in Digital Therapeutics Key Market Players Akili Interactive Labs, Inc. Lark Technologies, Inc. 2Morrow Inc. Click Therapeutics, Inc. Biofourmis Inc. Glooko, Inc. CureApp, Inc. Cognoa, Inc. Omada Health, Inc. Cara Care Neurotrack Technologies, Inc. Kaia Health ResMed Inc. Vida Health Vivante Health, Inc. Key Topics Covered: Executive SummaryScope of the Study1. Global Digital Therapeutics Market Overview1.1 Trends: Current and Future Impact Assessment1.1.1 Trend 1: Expansion across Therapeutic Area1.1.2 Trend 2: Integration with the Healthcare Ecosystem1.1.3 Trend 3: Utilization of Artificial Intelligence (AI) and Machine Learning (ML) with Digital Therapeutics1.2 Value Chain Analysis1.3 Funding Activities1.4 Regulatory Framework1.5 Patent Analysis2. Market Dynamics2.1.1 Impact Analysis2.1.2 Market Drivers2.1.3 Market Restraints2.1.4 Market Opportunities3. Global Digital Therapeutics Market Analysis (By Product Type), $Million, 2024-20353.1 Overview3.2 Growth-Share Matrix3.3 Product Type3.4 Software3.5 Devices4. Global Digital Therapeutics Market Analysis (By Application), $ Million, 2024-20354.1 Overview4.2 Growth-Share Matrix4.3 Application Summary4.4 Treatment/Patient Care-Related Applications4.4.1 Diabetes4.4.2 Neurological Disorders4.4.3 Smoking Cessation4.4.4 Chronic Respiratory Disorders4.4.5 Gastrointestinal Disorders4.4.6 Cardiovascular Disorders4.4.7 Medication Adherence4.4.8 Rehabilitation and Patient Care4.4.9 Others4.5 Preventive Applications4.5.1 Nutrition Management4.5.2 Lifestyle Management4.5.3 Others5. Global Digital Therapeutics Market Analysis (By Sales Channel), $Million, 2024-20355.1 Overview5.2 Sales Channel Summary5.3 Business-to-Business5.3.1 Insurance Providers/Corporate Employer5.3.2 Pharmaceutical Companies5.3.3 Others5.4 Business-to-Customer5.4.1 Patients5.4.2 Caregivers6. Global Digital Therapeutics Market Analysis (By Region), $ Million, 2024-20356.1 Regional Summary6.2 North America6.2.1 Regional Overview6.2.2 Driving Factors for Market Growth6.2.3 Factors Challenging the Market Growth6.2.4 U.S.6.2.5 Canada6.3 Europe6.3.1 Regional Overview6.3.2 Driving Factors for Market Growth6.3.3 Factors Challenging the Market Growth6.3.4 U.K.6.3.5 Germany6.3.6 France6.3.7 Italy6.3.8 Spain6.3.9 Rest-of-Europe6.4 Asia-Pacific6.4.1 Regional Overview6.4.2 Driving Factors for Market Growth6.4.3 Factors Challenging the Market Growth6.4.4 China6.4.5 Japan6.4.6 India6.4.7 Australia6.4.8 South Korea6.4.9 Rest-of-Asia-Pacific6.5 Latin America6.5.1 Regional Overview6.5.2 Driving Factors for Market Growth6.5.3 Factors Challenging the Market Growth6.5.4 Brazil6.5.5 Mexico6.5.6 Rest-of-Latin America6.6 Middle East and Africa6.6.1 Regional Overview6.6.2 Driving Factors for Market Growth6.6.3 Factors Challenging the Market Growth6.6.4 KSA6.6.5 U.A.E.6.6.6 Israel6.6.7 South Africa6.6.8 Rest-of-Middle East and Africa7. Global Digital Therapeutics Market - Competitive Benchmarking and Company Profiles7.1 Next Frontiers7.2 Competitive Analysis7.3 Global Ecosystem Glimpse7.4 Geographic Assessment7.4.1 Company Overview7.4.2 Product Portfolio7.4.3 Key Competitors7.4.4 Target Customers7.4.5 Analyst Perspective For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Digital Therapeutics Market Analysis and Forecasts, 2025-2035: Rising Fundings and Investment in Digital Therapeutics and Expanding Applications Driving Opportunities
The global digital therapeutics market is rapidly transforming healthcare with evidence-based software and devices that enhance both physical and behavioral health management. Key drivers include increased accessibility, patient engagement, data insights, and reduced healthcare costs. Notable developments in the market feature major collaborations between prominent firms like Vida Health and Click Therapeutics. With challenges like data privacy and reimbursement hindrances, expanding applications and rising investment present vast opportunities for growth. This dynamic market is fueled by technological advances, cost-effectiveness, and expanding global reach, signifying a new era in personalized, patient-centered care. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Digital Therapeutics Market - A Global and Regional Analysis: Focus on Product Type, Application, Sales Channel, and Country - Analysis and Forecast, 2025-2035" report has been added to global digital therapeutics market includes clinically validated software and devices that are evidence-based. These tools are intended for the treatment of a wide range of diseases and conditions. Furthermore, digital therapeutics can be used either on their own or in combination with other devices to manage both physical and behavioural health issues. China led the Asia-Pacific digital therapeutics market in 2024, driven by its large population facing chronic conditions like diabetes, hypertension, and cardiovascular diseases. Digital therapeutics provides effective and accessible solutions for managing these health issues. The Chinese government acknowledges the potential of digital therapeutics and is actively supporting its development and adoption to improve healthcare delivery and outcomes. How can this report add value to an organization?Product/Innovation Strategy: The global digital therapeutics market is extensively segmented across various categories, such as product type, application, sales channel, and region. Each region undergoes a detailed analysis based on digital therapeutics product type, application, and sales channel. This segmentation offers readers a clear overview of which digital therapeutics segments currently dominate the market, and which ones are well-positioned for growth in the Strategy: Synergistic activities represented the largest share of key developments, with approximately 64.44% of all developments in the global digital therapeutics market occurring between January 2020 and November Strategy: The global digital therapeutics market is home to numerous established players, each offering product portfolios that address a wide array of conditions. Key players analysed and profiled in the study include prominent companies providing diverse digital therapeutics solutions for treatment, patient care, and preventive Dynamics Impact Analysis: Increased Accessibility of Care Improved Patient Engagement and Adherence Enhanced Data Collection and Analysis Reduced Costs of Healthcare Delivery Market Demand Drivers Multiple Benefits Provided by Digital Therapeutics over Traditional Treatment Continuous Technological Advancements Driving the Adoption of Digital Therapeutics Increasing Demand for Cost-Effective Solutions Creating a Demand for Digital Therapeutics Market Restraints: Data Privacy and Security Concerns Lack of Standardized Reimbursement Models Market Opportunities: Expanding Applications of Digital Therapeutics Rising Fundings and Investment in Digital Therapeutics Key Market Players Akili Interactive Labs, Inc. Lark Technologies, Inc. 2Morrow Inc. Click Therapeutics, Inc. Biofourmis Inc. Glooko, Inc. CureApp, Inc. Cognoa, Inc. Omada Health, Inc. Cara Care Neurotrack Technologies, Inc. Kaia Health ResMed Inc. Vida Health Vivante Health, Inc. Key Topics Covered: Executive SummaryScope of the Study1. Global Digital Therapeutics Market Overview1.1 Trends: Current and Future Impact Assessment1.1.1 Trend 1: Expansion across Therapeutic Area1.1.2 Trend 2: Integration with the Healthcare Ecosystem1.1.3 Trend 3: Utilization of Artificial Intelligence (AI) and Machine Learning (ML) with Digital Therapeutics1.2 Value Chain Analysis1.3 Funding Activities1.4 Regulatory Framework1.5 Patent Analysis2. Market Dynamics2.1.1 Impact Analysis2.1.2 Market Drivers2.1.3 Market Restraints2.1.4 Market Opportunities3. Global Digital Therapeutics Market Analysis (By Product Type), $Million, 2024-20353.1 Overview3.2 Growth-Share Matrix3.3 Product Type3.4 Software3.5 Devices4. Global Digital Therapeutics Market Analysis (By Application), $ Million, 2024-20354.1 Overview4.2 Growth-Share Matrix4.3 Application Summary4.4 Treatment/Patient Care-Related Applications4.4.1 Diabetes4.4.2 Neurological Disorders4.4.3 Smoking Cessation4.4.4 Chronic Respiratory Disorders4.4.5 Gastrointestinal Disorders4.4.6 Cardiovascular Disorders4.4.7 Medication Adherence4.4.8 Rehabilitation and Patient Care4.4.9 Others4.5 Preventive Applications4.5.1 Nutrition Management4.5.2 Lifestyle Management4.5.3 Others5. Global Digital Therapeutics Market Analysis (By Sales Channel), $Million, 2024-20355.1 Overview5.2 Sales Channel Summary5.3 Business-to-Business5.3.1 Insurance Providers/Corporate Employer5.3.2 Pharmaceutical Companies5.3.3 Others5.4 Business-to-Customer5.4.1 Patients5.4.2 Caregivers6. Global Digital Therapeutics Market Analysis (By Region), $ Million, 2024-20356.1 Regional Summary6.2 North America6.2.1 Regional Overview6.2.2 Driving Factors for Market Growth6.2.3 Factors Challenging the Market Growth6.2.4 U.S.6.2.5 Canada6.3 Europe6.3.1 Regional Overview6.3.2 Driving Factors for Market Growth6.3.3 Factors Challenging the Market Growth6.3.4 U.K.6.3.5 Germany6.3.6 France6.3.7 Italy6.3.8 Spain6.3.9 Rest-of-Europe6.4 Asia-Pacific6.4.1 Regional Overview6.4.2 Driving Factors for Market Growth6.4.3 Factors Challenging the Market Growth6.4.4 China6.4.5 Japan6.4.6 India6.4.7 Australia6.4.8 South Korea6.4.9 Rest-of-Asia-Pacific6.5 Latin America6.5.1 Regional Overview6.5.2 Driving Factors for Market Growth6.5.3 Factors Challenging the Market Growth6.5.4 Brazil6.5.5 Mexico6.5.6 Rest-of-Latin America6.6 Middle East and Africa6.6.1 Regional Overview6.6.2 Driving Factors for Market Growth6.6.3 Factors Challenging the Market Growth6.6.4 KSA6.6.5 U.A.E.6.6.6 Israel6.6.7 South Africa6.6.8 Rest-of-Middle East and Africa7. Global Digital Therapeutics Market - Competitive Benchmarking and Company Profiles7.1 Next Frontiers7.2 Competitive Analysis7.3 Global Ecosystem Glimpse7.4 Geographic Assessment7.4.1 Company Overview7.4.2 Product Portfolio7.4.3 Key Competitors7.4.4 Target Customers7.4.5 Analyst Perspective For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-04-2025
- Health
- Business Wire
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
NEW YORK--(BUSINESS WIRE)--Click Therapeutics, Inc., ('Click') a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing authorization for the first prescription digital therapeutic for the preventive treatment of episodic migraine. FDA granted the De Novo Classification Request for the company's prescription digital therapeutic, CT-132, for the preventive treatment of episodic migraine in patients 18 years of age and older. It is intended for adjunctive use alongside acute and/or other preventive treatments for migraine. The marketing authorization for CT-132 is based on data from the ReMMi-D (Re duction in M onthly Mi graine D ays, NCT05853900) study in patients taking standard-of-care prescription migraine medications (acute, preventive first-line, and preventive second-line), where CT-132 met its primary endpoint. Clinical results from the ReMMiD-C bridging study (NCT06004388), which showed that CT-132 performed similarly in patients taking calcitonin gene-related peptide (CGRP) inhibitors, were also submitted in the De Novo and included in the product's FDA premarket review. 'This marks a significant milestone for the more than 37 million adults in the US who live with migraine,' said Shaheen Lakhan, MD, PhD, FAAN, chief medical and scientific officer of Click Therapeutics. 'As a groundbreaking digital therapeutic for migraine prevention, CT-132 offers eligible patients a new path to reducing the burden caused by migraine, one they can access anywhere via an evidence-based mobile application on their smartphone, significantly improving accessibility and expanding care to patients.' Click Therapeutics recently presented CT-132 pivotal study results at the American Academy of Neurology Annual Meeting, where co-investigator Stewart J. Tepper, MD, Vice President of the New England Institute for Neurology and Headache and scientific advisor to Click shared in a post-conference Medscape article, 'I think this is very exciting as a clinician who takes care of patients because we don't have anything like this in our migraine armamentarium. We know that behavioral techniques are helpful adjunctively, but large areas of the country just don't have access to them.' 'With this landmark, first-in-class FDA authorization in episodic migraine, Click's interventions have now demonstrated clinically meaningful benefit across three unique therapeutic areas, including psychiatry, cardiometabolic disease and now neurology,' said David Benshoof Klein, chief executive officer of Click Therapeutics. 'As the first authorization in our neurology pipeline, and the first of our PDTs to target and successfully treat a pain-related condition, it confirms the power of Click's platform to deliver meaningful outcomes across therapeutic areas.' Built on Click's industry-leading AI-enabled platform, CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Click Therapeutics designs patient-centric applications like CT-132 by incorporating storytelling, user research, and elements of consumer technology to increase engagement and drive improved clinical outcomes, with the goal of delivering personalized treatment for effective migraine management. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy. CT-132 is thus well-positioned for further development in the future as a software-enhanced drug™ therapy. Click's software-enhanced drug therapies combine software with pharmacotherapy to create software-enhanced drug™ treatment options, targeting the unique needs of a specific medication to deliver added clinical benefit to patients. Click launched its new product offering, Click SE™, in October 2024 to pioneer this new therapeutic category in response to increasing interest in the U.S. Food and Drug Administration (FDA) draft guidance on Prescription Drug-Use Related Software (PDURS). This marketing authorization announcement follows Click's recent Series C funding round news, announced in March 2025. Indication: The CT-132 prescription digital therapeutic is indicated for the preventive treatment of episodic migraine in patients 18 years of age and older. It is intended for adjunctive use alongside acute and / or other preventive treatments for migraine. Safety Information: There are no contraindications to using CT-132. CT-132 is not intended to be used as a standalone therapy. CT-132 does not replace or substitute other migraine treatments, including medication for migraine. Patients should continue their current treatment as directed. About the ReMMi-D Pivotal Study and ReMMiD-C Bridging study The indications for use for CT-132 are supported by the results from two double-blind decentralized randomized controlled trials, a pivotal study (ReMMi-D) and a bridging study (ReMMiD-C). The pivotal ReMMi-D study evaluated the effectiveness and safety of CT-132 for the prevention of episodic migraine in patients 18 years and older, compared to a sham digital control and included patients (n=558) on the most commonly prescribed migraine medications. ReMMiD-C was designed identically to ReMMi-D but required that participants (n=110) be taking at least one calcitonin gene-related peptide (CGRP) inhibitor, though participants were also permitted use of non–migraine-specific acute or preventive medications. The study designs mirrored those of contemporary randomized control trials for migraine drugs. However, unlike in drug studies, patients continued their existing migraine medications without any washout period, so the additive treatment effect of CT-132 on top of background pharmacotherapy could be evaluated. Both studies demonstrated that CT-132 reduced monthly migraine days (MMDs) compared to a sham digital control in patients already using acute and preventive migraine medications, with no device-related adverse events reported. At the completion of the pivotal ReMMi-D study, CT-132 demonstrated a statistically significant reduction in monthly migraine days (MMDs) after 12 weeks of treatment compared to the sham digital control (n=568, ITT population; treatment difference: –0.9 MMDs; p =0.005). Participants in the treatment arm experienced a mean reduction of –3.04 MMDs by the end of the intervention. Further, migraine related quality of life, assessed by the Migraine-Specific Quality-of-Life Questionnaire (MSQ, revealed a difference between the CT-132 and sham digital control arms from as early as 4 weeks and through weeks 8 and 12. Migraine disability, as measured by the Migraine Disability Assessment (MIDAS) score, improved more in the CT-132 arm than in the sham arm at the end of treatment. Note that the analysis of secondary effectiveness endpoints did not include multiplicity adjustment or formal hypothesis testing. Engagement and adherence were high and sustained over the full 12-week duration of the treatment, with a median of 81 daily lessons out of 84 completed by those receiving the sham digital control and a median of 84 completed by those receiving CT-132. CT-132 was well-tolerated, with no discontinuations due to treatment-emergent adverse events (TEAEs). The ReMMiD-C bridging study provided supportive information, also evaluated versus a sham digital control but without formal hypothesis testing, that demonstrated similar performance of CT-132 in patients taking the new-class of migraine-specific medications, CGRP inhibitors. About Migraine Migraine is a complex and debilitating condition that affects more than 37 million adults and is the second leading cause of disability in the United States. 1,2 It is characterized by episodes of moderate-to-severe headache and is generally associated with nausea and increased sensitivity to light and sound. 3 For those living with migraine, attacks unfold over hours to days and negatively impact key domains of life including employment, educational attainment, and relationships. 4 Despite the availability of preventive migraine medications, there remains a significant unmet need in migraine management. Many patients continue to experience frequent and debilitating attacks, even when using these drugs as prescribed. 5 About Prescription Digital Therapeutics Prescription Digital Therapeutics (PDTs) deliver evidence-based treatments directly to a patient via their smartphone in the form of a mobile app. With PDTs, the software is the treatment. PDTs are prescribed by a physician to treat a disease or condition, and as such are clinically validated and FDA-regulated. PDTs can be used independently or in combination with traditional pharmaceutical treatments. About Click Therapeutics Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease. Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click's platform are regulated, clinically validated prescription mobile applications that are being developed to address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. In 2024, in response to FDA guidance on prescription drug use-related software (PDURS) and building off the capabilities of our platform, we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients. To date, three Click Therapeutics devices have received FDA marketing authorizations. The company's self-developed CT-132, a first-in-class prescription digital therapeutic for preventing episodic migraine, was granted De Novo classification by the FDA. Click Therapeutics, in collaboration with Otsuka, developed Rejoyn™, which became the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms. Additionally, the company expanded its portfolio into cardiometabolic disease with AspyreRx, which received FDA marketing authorization for the treatment of type 2 diabetes. Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit and connect with us on LinkedIn. References
